Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats.
Neuroreport May 11, 1998 DOI: 10.1097/00001756-199805110-00004 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Rats |
| Intervention | 18-Methoxycoronaridine (18-MC) |
| Keywords | Opioid dependence treatment Opioid addiction therapy Opioid withdrawal management Drug dependence treatment Substance abuse therapy Drug research Medicinal chemistry Pharmaceutical science Drug action Experimental pharmacology Preclinical research Animal studies In vivo study Rat model research Experimental research 18-methoxycoronaridine 18-mc Ibogaine derivative Novel opioid compound Opioid antagonist candidate |
| Citations | 35 |
| Key findings | 18-MC attenuated five of seven signs of morphine withdrawal in rats. |
Abstract
Ibogaine, an alkaloid found in the root bark of the African shrub Tabernanthe iboga, has been claimed to interrupt opioid dependence in humans; in animals, it has been shown to inhibit morphine self-administration and to attenuate signs of morphine withdrawal. However, ibogaine has some neurotoxicity, and because of this, efficacious and safer congeners of ibogaine have been sought, 18-Methoxycoronaridine (18-MC), a novel iboga alkaloid congener, has been shown, in animals, to mimic the effects of ibogaine on morphine self-administration without producing any ibogaine-like neurotoxiticity. In the present study, 18-MC was shown to attenuate five of seven signs of morphine withdrawal in rats. The data suggest that 18-MC will ameliorate symptoms of opioid dependence in humans.